Suppliers / Lilly France S.A.S

Lilly France S.A.S

France Updated 9 July 2026

Lilly France S.A.S is a finished-dose manufacturer based in France. It appears in 3 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with MINSA (CR), NPRA (MY) and DIGEMAPS (DO). Its GMP standing is certified by NAFDAC (NG), EMA and ANVISA (Brazil), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 29 September 2023 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
3
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 29 September 2023 VAI US FDA
  • 15 January 2021 VAI US FDA
  • 4 April 2017 VAI US FDA
  • 3 May 2016 VAI US FDA
  • 16 September 2014 NAI US FDA
  • 28 September 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
FEGERSHEIM, France Not on file
France, France 3002807475
Fegershiem, Nigeria Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None
NPRA (MY) 1 None
DIGEMAPS (DO) 1 None
NAFDAC (NG) None 1
EMA None 1
ANVISA (Brazil) None 1
US FDA None 1

Questions about Lilly France S.A.S

Does Lilly France S.A.S hold a US DMF or a CEP?
No active US drug master file or valid CEP is on record for Lilly France S.A.S. It does have 3 filings with 3 regulators, so it is registered, just not with the two strong registers buyers usually screen on.
Is Lilly France S.A.S FDA-registered?
One site operated by Lilly France S.A.S carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Lilly France S.A.S's last inspection go?
The most recent inspection on record closed on 29 September 2023 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 6 inspections are on file.
Where does Lilly France S.A.S manufacture?
3 registered sites are on record, in France and Nigeria (Fegersheim, France and Fegershiem). Every site is listed on this page with the register it came from.
Which regulators recognise Lilly France S.A.S's GMP?
Current GMP certificates are on record from NAFDAC (NG), EMA, ANVISA (Brazil) and US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Lilly France S.A.S comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 September 2023.

Comparable suppliers

AdhexPharma also in France Advanced Accelerator Applications also in France Aspen Notre Dame De Bondeville also in France Astrazeneca Dunkerque Production also in France Astrea Fontaine also in France

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates